Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Coya Therapeutics, Inc. (NASDAQ:COYA) has been assigned a consensus recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $16.00.

Several research firms have recently issued reports on COYA. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Lake Street Capital reiterated a “buy” rating and set a $17.00 target price on shares of Coya Therapeutics in a research note on Wednesday, November 5th. Wall Street Zen upgraded Coya Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. Chardan Capital restated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Thursday, January 8th. Finally, BTIG Research lifted their target price on shares of Coya Therapeutics from $15.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th.

Coya Therapeutics Stock Up 1.1%

Coya Therapeutics stock opened at $4.65 on Monday. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29. The business has a fifty day moving average of $5.41 and a two-hundred day moving average of $5.89. The firm has a market cap of $97.28 million, a P/E ratio of -4.19 and a beta of 0.27.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $3.70 million. Equities analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current year.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. Prosperity Wealth Management Inc. increased its holdings in shares of Coya Therapeutics by 16.4% in the 3rd quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after acquiring an additional 3,350 shares during the period. JPMorgan Chase & Co. acquired a new stake in Coya Therapeutics during the third quarter valued at $28,000. Lantern Wealth Advisors LLC bought a new position in Coya Therapeutics during the third quarter valued at about $66,000. Jane Street Group LLC lifted its position in Coya Therapeutics by 101.7% during the 1st quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock worth $169,000 after acquiring an additional 13,176 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in Coya Therapeutics during the 2nd quarter valued at $119,000. Institutional investors own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.